rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Jacob Chacko

Director

Company insider

Files Form 4 as: Director, 4D Molecular Therapeutics; President and CEO, Oric Pharmaceuticals; Director, Turning Point Therapeutics; Chief Financial Officer, Ignyta.

In numbers

Trades disclosed
107
Buys
13
Sells
36
Bought
$3.1M
Sold
$6.6M
Companies
4
Companies where not an officer
2
First trade
30 May 2014
Last trade
17 Jun 2026
Last filed
18 Jun 2026

Companies traded

Where they are an officer
ORIC Oric PharmaceuticalsDirector, Officer · Biotechnology · last 2 Jan 20266 buys · 35 sells
IgnytaOfficer · last 8 Feb 20187 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
FDMT 4D Molecular TherapeuticsDirector · Biotechnology · last 17 Jun 20260 buys · 1 sell
Turning Point TherapeuticsDirector · last 15 Jun 20200 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
30Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
17 Jun 2026filed 18 Jun 2026FDMT 4D Molecular Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—50,000 at $0.00filing
17 Jun 2026filed 18 Jun 2026FDMT 4D Molecular Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—50,000 at $0.00filing
2 Jan 2026filed 6 Jan 2026ORIC Oric Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—675,000 at $0.00filing
2 Jan 2026filed 6 Jan 2026ORIC Oric Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—112,500 at $0.00filing
2 Jan 2026filed 6 Jan 2026ORIC Oric Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—675,000 at $0.00filing
2 Jan 2026filed 6 Jan 2026ORIC Oric Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—112,500 at $0.00filing
16 Dec 2025filed 17 Dec 2025ORIC Oric PharmaceuticalsBiotechnologySEC FORM 4 Sold$302K33,374 at $9.06filing
15 Dec 2025filed 17 Dec 2025ORIC Oric Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—22,000 at $0.00filing
15 Dec 2025filed 17 Dec 2025ORIC Oric Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—28,333 at $0.00filing
15 Dec 2025filed 17 Dec 2025ORIC Oric Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—33,333 at $0.00filing
15 Dec 2025filed 17 Dec 2025ORIC Oric PharmaceuticalsBiotechnologySEC FORM 4 Code M—83,666 at $0.00filing
6 Oct 2025filed 8 Oct 2025ORIC Oric PharmaceuticalsBiotechnologySEC FORM 4 Sold$462K37,461 at $12.32filing
1 Oct 2025filed 2 Oct 2025ORIC Oric PharmaceuticalsBiotechnologySEC FORM 4 Sold$639K53,001 at $12.05filing
30 Sep 2025filed 2 Oct 2025ORIC Oric PharmaceuticalsBiotechnologySEC FORM 4 Sold$415K34,538 at $12.01filing
22 Sep 2025filed 24 Sep 2025ORIC Oric PharmaceuticalsBiotechnologySEC FORM 4 Sold$1.4M125,000 at $10.80filing
17 Jun 2025filed 20 Jun 2025FDMT 4D Molecular Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—22,500 at $0.00filing
2 Jan 2025filed 3 Jan 2025ORIC Oric Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—600,000 at $0.00filing
2 Jan 2025filed 3 Jan 2025ORIC Oric Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—100,000 at $0.00filing
16 Dec 2024filed 17 Dec 2024ORIC Oric PharmaceuticalsBiotechnologySEC FORM 4 Sold$204K24,660 at $8.28filing
15 Dec 2024filed 17 Dec 2024ORIC Oric Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—16,667 at $0.00filing

News

Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 14,000 Shares of Company StockORIC · themarketsdaily.com · 22 Oct 2026

0 headlines in the last 90 days name Jacob Chacko; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.

Sectors

Health Care42
Not placed7

Buys in green, sells in red, by the company’s sector.

Related people

Dominic PiscitelliChief Financial Officer · Chief Financial Officer at Oric Pharmaceuticals, filing Form 4 there in the last year
Richard A. HeymanDirector · Director at Oric Pharmaceuticals, filing Form 4 there in the last year
Mardi DierEVP and CFO · Director at Oric Pharmaceuticals, filing Form 4 there in the last year
Steven L. HoerterPresident and CEO · Director at Oric Pharmaceuticals, filing Form 4 there in the last year
Pratik S. MultaniDirector · Chief Medical Officer at Oric Pharmaceuticals, filing Form 4 there in the last year
Scott BizilyChief Legal Officer · Also traded FDMT in the last 90 days
David KirnDirector and Officer · Also traded FDMT in the last 90 days